Siemens Healthineers Faces a $100 Million Test of Confidence

A major U.S. partnership provides fleeting gains as Siemens Healthineers faces a 400M euro tariff hit, currency losses, and China struggles, testing its full-year growth target.

A major ten-year partnership worth over $100 million with Arizona's Onvida Health has failed to provide lasting momentum for Siemens Healthineers. The deal, announced Tuesday to modernize CT and MRI systems in the growing Yuma region, initially sent shares up nearly five percent. By the week's end, however, the stock had settled at 37.87 euros, cementing a painful year-to-date loss of 14.78 percent. The fleeting rally underscores a stark reality: operational wins are being overwhelmed by a perfect storm of financial headwinds.

The most significant pressure comes from U.S. trade policy. Management now expects adjusted EBIT for fiscal 2026 to be reduced by approximately 400 million euros due to tariffs, double the impact of the prior year when the levies were only in effect for half the period. This forecast stands even after the company has initiated countermeasures. Compounding the pain, adverse currency movements are projected to shave off an additional 200 to 250 million euros. The Imaging and Advanced Therapies divisions are particularly exposed.

Simultaneously, the company's diagnostics business in China continues to struggle. Anti-corruption measures and centralized procurement have pushed down reimbursement rates, leading to a three percent regional sales decline already in the first quarter. This weakness prompted Siemens Healthineers to warn in March that second-quarter revenue growth would fall short of its projected 5 to 6 percent range.

Amid these challenges, the firm is pursuing strategic clinical partnerships. It recently secured an agreement with Australian biotech Radiopharm Theranostics for the U.S. manufacturing and distribution of RAD101. This fluorine-18 marked diagnostic agent, which received FDA Fast Track designation in June 2025, is intended for an upcoming Phase 3 trial aimed at more precisely detecting brain metastases. The molecule’s 110-minute half-life presents a logistical challenge, one Siemens Healthineers plans to address using its nationwide network of radiopharmacies to supply trial sites. The annual U.S. patient pool for this application is estimated at over 300,000.

The company’s leadership maintains its full-year target for comparable revenue growth of 5 to 6 percent. All eyes are now on May 7, when Siemens Healthineers releases its complete second-quarter results. This report will serve as a critical stress test, revealing the precise depth of the tariff and currency impacts and offering evidence on whether the Chinese market is beginning to stabilize.